Advanced Cell Technology Announces 2011 Financial Results

Advanced Cell Research, Inc., a leader in the field of regenerative medicine, today announced year-end results for the year ended December 31, 2011. The Company utilized $13.6 million in cash for operations while the year, compared to $8.8 million in the year-before period. The increase in cash utilization resulted primarily from ACT's ongoing clinical activities in the US and Europe. ACT ended the year with cash and cash equivalents of $13.1 million, compared to $15.9 million in cash and cash equivalents in the year-before period.

Advanced Cell Research, Inc., is a biotechnology company applying cellular innovation in the field of regenerative medicine. For more information, visit�www.advancedcell.com.